Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland
Trodelvy 200 mg powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion. Off-white to yellowish powder. |
One vial of powder contains 200 mg sacituzumab govitecan.
After reconstitution, one mL of solution contains 10 mg sacituzumab govitecan.
Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC). Sacituzumab is a humanised monoclonal antibody (hRS7 IgG1Îș) that recognises Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a hydrolysable linker. Approximately 7-8 molecules of SN-38 are attached to each antibody molecule.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Sacituzumab govitecan |
Sacituzumab govitecan binds to Trop-2-expressing cancer cells and is internalised with the subsequent release of SN-38 from a hydrolysable linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. |
| List of Excipients |
|---|
|
2-(N-morpholino)ethane sulfonic acid (MES) |
Type I colourless, clear glass 50 mL vial, with an elastomeric butyl stopper and sealed with an aluminum flip-off overseal containing 200 mg of sacituzumab govitecan.
Each pack contains one vial.
Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland
EU/1/21/1592/001
Date of first authorisation: 22 November 2021
| Drug | Countries | |
|---|---|---|
| TRODELVY | Estonia, Finland, Ireland, Israel, Poland, Romania, Turkey, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
